Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Imatinib mesylate
Drug ID BADD_D01137
Description Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Indications and Usage For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
Marketing Status approved
ATC Code L01EA01
DrugBank ID DB00619
KEGG ID D01441
MeSH ID D000068877
PubChem ID 123596
TTD Drug ID D0AZ3C
NDC Product Code 11722-052; 66499-0073; 71052-670; 73309-059; 0078-0649; 60505-2901; 64679-794; 68001-490; 72819-186; 67877-633; 67877-634; 68001-491; 0054-0248; 42385-720; 54893-0066; 59923-723; 67184-0533; 68382-244; 70771-1394; 72485-203; 60505-2900; 60687-192; 60687-203; 67184-0532; 0054-0249; 70771-1395; 59923-724; 82009-087; 55111-939; 65344-0020; 0078-0401; 59651-240; 0093-7629; 64679-793; 72606-556; 62756-875; 0093-7630; 0904-6901; 42385-316; 59651-610; 81955-0002; 47335-475; 72485-202; 0904-6621; 54893-0005; 47335-472; 68382-245; 72606-557; 72819-185; 82009-086; 59651-241
UNII 8A1O1M485B
Synonyms Imatinib Mesylate | Mesylate, Imatinib | Imatinib Methanesulfonate | Methanesulfonate, Imatinib | STI571 | STI-571 | STI 571 | Gleevec | Glivec | ST 1571 | ST1571 | CGP 57148 | CGP57148B | CGP-57148 | CGP57148 | Imatinib | Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
Chemical Information
Molecular Formula C30H35N7O4S
CAS Registry Number 220127-57-1
SMILES CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)( =O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ileus07.13.01.001--
Increased appetite08.01.09.027; 14.03.01.003---
Increased tendency to bruise01.01.03.005; 23.06.01.009; 24.07.06.012---
Infection11.01.08.002---
Inflammatory bowel disease07.08.01.016---
Influenza11.05.03.001; 22.07.02.001---
Insomnia17.15.03.002; 19.02.01.002--
Interstitial lung disease10.02.01.033; 22.01.02.003---
Intestinal obstruction07.13.01.002---
Intracranial pressure increased17.07.02.002---
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Joint swelling15.01.02.004---
Lacrimation increased06.08.02.004--
Laryngeal pain22.12.03.010--
Lethargy08.01.01.008; 17.02.04.003; 19.04.04.004--
Leukopenia01.02.02.001---
Libido decreased19.08.03.001; 21.03.02.005--
Lichen planus23.03.08.001---
Lower respiratory tract infection11.01.09.002; 22.07.01.002---
Lymphadenopathy01.09.01.002---
Lymphopenia01.02.02.002---
Macular oedema06.04.06.005---
Malaise08.01.01.003--
Melaena07.12.02.004; 24.07.02.013---
Memory impairment17.03.02.003; 19.20.01.003--
Menstruation irregular05.05.01.008; 21.01.01.005--
Migraine17.14.02.001; 24.03.05.003---
Mouth ulceration07.05.06.004---
Muscle spasms15.05.03.004--
Muscular weakness15.05.06.001; 17.05.03.005--
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 9 Pages